GB201818316D0 - T-cells for use in T-cell therapy - Google Patents

T-cells for use in T-cell therapy

Info

Publication number
GB201818316D0
GB201818316D0 GBGB1818316.0A GB201818316A GB201818316D0 GB 201818316 D0 GB201818316 D0 GB 201818316D0 GB 201818316 A GB201818316 A GB 201818316A GB 201818316 D0 GB201818316 D0 GB 201818316D0
Authority
GB
United Kingdom
Prior art keywords
cells
cell therapy
therapy
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1818316.0A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Telonostix Ltd
Original Assignee
Telonostix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telonostix Ltd filed Critical Telonostix Ltd
Priority to GBGB1818316.0A priority Critical patent/GB201818316D0/en
Publication of GB201818316D0 publication Critical patent/GB201818316D0/en
Priority to PCT/GB2019/053148 priority patent/WO2020095048A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
GBGB1818316.0A 2018-11-09 2018-11-09 T-cells for use in T-cell therapy Ceased GB201818316D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1818316.0A GB201818316D0 (en) 2018-11-09 2018-11-09 T-cells for use in T-cell therapy
PCT/GB2019/053148 WO2020095048A1 (en) 2018-11-09 2019-11-07 T-cells for use in t-cell therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1818316.0A GB201818316D0 (en) 2018-11-09 2018-11-09 T-cells for use in T-cell therapy

Publications (1)

Publication Number Publication Date
GB201818316D0 true GB201818316D0 (en) 2018-12-26

Family

ID=64739587

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1818316.0A Ceased GB201818316D0 (en) 2018-11-09 2018-11-09 T-cells for use in T-cell therapy

Country Status (2)

Country Link
GB (1) GB201818316D0 (en)
WO (1) WO2020095048A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8383099B2 (en) * 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US9512401B2 (en) * 2010-10-01 2016-12-06 Board Of Regents, The University Of Texas System B and T lymphocyte attenuator marker for use in adoptive T-cell therapy

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BAIRD, D. M.; ROWSON, J.; WYNFORD-THOMAS, D.; KIPLING, D.: "Extensive allelic variation and ultrashort telomeres in senescent human cells", NAT GENET, vol. 33, 2003, pages 203 - 207, XP002246105, DOI: doi:10.1038/ng1084
BODNAR, A. G.; KIM, N. W.; EFFROS, R. B.; CHIU, C. P.: "Mechanism of telomerase induction during T cell activation", EXP CELL RES, vol. 228, 1996, pages 58 - 64
BRUDNO, J. N. ET AL.: "Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease", J CLIN ONCOL, vol. 34, 2016, pages 1112 - 1121, XP055498788, DOI: doi:10.1200/JCO.2015.64.5929
CAPPER, R. ET AL.: "The nature of telomere fusion and a definition of the critical telomere length in human cells", GENES DEV, vol. 21, 2007, pages 2495 - 2508
D'ADDA DI FAGAGNA, F. ET AL.: "A DNA damage checkpoint response in telomere-initiated senescence", NATURE, vol. 426, 2003, pages 194 - 198
GHOSH, A. ET AL.: "Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity", NAT MED, vol. 23, 2017, pages 242 - 249
HARLEY, C. B.; FUTCHER, A. B.; GREIDER, C. W.: "Telomeres shorten during ageing of human fibroblasts", NATURE, vol. 345, 1990, pages 458 - 460
PARK, J. H. ET AL.: "Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia", N ENGL J MED, vol. 378, 2018, pages 449 - 459
PORTER, D. L. ET AL.: "Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia", SCIENCE TRANSLATIONAL MEDICINE, vol. 7, 2015, pages 303ra139
ROTH, A. ET AL.: "Telomerase levels control the lifespan of human T lymphocytes", BLOOD, vol. 102, 2003, pages 849 - 857
VAZIRI, H. ET AL.: "Loss of telomeric DNA during aging of normal and trisomy 21 human lymphocytes", AM J HUM GENET, vol. 52, 1993, pages 661 - 667, XP009023249

Also Published As

Publication number Publication date
WO2020095048A1 (en) 2020-05-14

Similar Documents

Publication Publication Date Title
IL266511A (en) Long acting il-2 receptor beta-biased agonist and a vaccine combination for use in treating cancer
PL3755384T3 (en) Portable far-uvc device
AU201814159S (en) Portable device holder
IL261788A (en) Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
GB201604492D0 (en) Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
GB201604494D0 (en) Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers
IL263513A (en) Improved adoptive t-cell therapy
IL261787A (en) Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
GB201510758D0 (en) Novel TNFa structure for use in therapy
EP3538008A4 (en) Selecting a medical device for use in a medical procedure
IL283487A (en) Compounds useful in hiv therapy
IL288728A (en) Anti-sortilin antibodies for use in therapy
SG11202010676TA (en) Improved t-cell therapy
EP3996801C0 (en) Medical device
EP3761870A4 (en) Handheld devices for use in medical procedures
IL284053A (en) Novel compounds and their use in therapy
IL280660A (en) Compounds useful in hiv therapy
CA183317S (en) Therapy pack
GB201702160D0 (en) Inhibitors for use in therapy
IL284981A (en) Semaphorin-4d antagonists for use in cancer therapy
CA183316S (en) Therapy pack
GB201819611D0 (en) Improvements in tools
IL283687A (en) Usp19 inhibitors for use in therapy
GB201615844D0 (en) Agents for use in therapy
ZA202100300B (en) Grinding device

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)